Ultralife (NASDAQ:ULBI) Announces Earnings Results

Ultralife (NASDAQ:ULBI) issued its earnings results on Tuesday. The technology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12), Zacks reports. Ultralife had a net margin of 0.92% and a return on equity of 1.66%. The business had revenue of $48.48 million for the quarter, compared to the consensus estimate of $57.00 million.

Here are the key takeaways from Ultralife’s conference call:

• Ultralife reported Q4 revenue of $48.5 million (up 10.6% YoY) and FY2025 revenue of $191.2 million, with backlog rising to $110.2 million (≈58% of TTM sales) that management expects to largely ship in 2026.
• A one-time non-cash intangible asset impairment (~$12.2M) and related charges produced a Q4 operating loss of $10.6 million and a GAAP net loss of $7.4 million ($0.45/share), leading to a full-year operating loss of $5.9M.
• The Battery & Energy segment strengthened—Q4 revenues of $45.9 million (up 15.1%) and gross margin improved to 25.1% (+170 bps)—while new products (Conformal wearable battery shipping, Thin Cell validated, X5‑SuperLite in production) and the Electrochem integration expand vertical integration and addressable markets.
• Communications Systems revenue declined to $2.6 million (‑35%) due to order timing, but management is targeting a $25 million baseline and expects 2026 product launches (A2303 amplifier, ruggedized server variants, Crescent wearable) to drive a rebound.
• Liquidity and adjusted operating metrics appear solid—Q4 adjusted EBITDA of $5.7 million (11.7% of sales), TTM adjusted EBITDA of $17.3M (9%), working capital of $68.5M, current ratio 2.8, and acquisition debt principal reduced by $4.8M in 2025.

Ultralife Price Performance

Ultralife stock traded up $0.36 during midday trading on Wednesday, reaching $6.09. 33,400 shares of the stock were exchanged, compared to its average volume of 42,452. The company’s fifty day moving average is $6.12 and its 200-day moving average is $6.29. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.42 and a current ratio of 2.99. The firm has a market cap of $101.32 million, a PE ratio of 61.63 and a beta of 0.88. Ultralife has a 52 week low of $4.07 and a 52 week high of $9.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Ultralife in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Insider Buying and Selling

In other news, Director Bradford T. Whitmore purchased 28,588 shares of Ultralife stock in a transaction dated Tuesday, December 16th. The stock was purchased at an average cost of $5.70 per share, for a total transaction of $162,951.60. Following the transaction, the director directly owned 1,235,631 shares of the company’s stock, valued at approximately $7,043,096.70. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have acquired 53,000 shares of company stock valued at $300,838. 40.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultralife

A number of institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC purchased a new stake in shares of Ultralife during the 4th quarter valued at $44,000. XTX Topco Ltd raised its position in Ultralife by 19.9% during the fourth quarter. XTX Topco Ltd now owns 15,456 shares of the technology company’s stock valued at $88,000 after purchasing an additional 2,569 shares in the last quarter. Rothschild Wealth LLC bought a new stake in Ultralife during the fourth quarter worth about $400,000. Heron Bay Capital Management purchased a new position in shares of Ultralife in the 4th quarter worth about $127,000. Finally, Jane Street Group LLC purchased a new position in shares of Ultralife during the 4th quarter valued at about $75,000. Institutional investors own 30.68% of the company’s stock.

Ultralife Company Profile

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.